A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations.
Eunbin KwagSoo-Dam KimSeong Hoon ShinChulho OakSo-Jung ParkJun-Yong ChoiSeong Hoon YoonIn-Cheol KangMi-Kyung JeongHyun Woo LeeSun-Hwi BangJi Woong SonSanghun LeeSeung Joon KimHwa Seung YooPublished in: Integrative cancer therapies (2024)
Clinical Research Information Service (CRIS) of the Republic of Korea, https://cris.nih.go.kr/ (ID: KCT0005414).
Keyphrases
- combination therapy
- small cell lung cancer
- open label
- locally advanced
- squamous cell carcinoma
- epidermal growth factor receptor
- advanced non small cell lung cancer
- mental health
- clinical trial
- rectal cancer
- healthcare
- phase ii study
- tyrosine kinase
- radiation therapy
- phase ii
- phase iii
- brain metastases
- randomized controlled trial
- lymph node